Medical Developments International (ASX:MVP) 3-Year Revenue Growth Rate

: 4.20% (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

Medical Developments International's Revenue per Share for the six months ended in Dec. 2023 was A$0.18.

During the past 12 months, Medical Developments International's average Revenue per Share Growth Rate was 15.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 4.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 4.00% per year. During the past 10 years, the average Revenue per Share Growth Rate was 7.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Medical Developments International was 25.00% per year. The lowest was -6.50% per year. And the median was 7.40% per year.

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medical Developments International 3-Year Revenue Growth Rate Distribution

For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Medical Developments International's 3-Year Revenue Growth Rate falls into.

Medical Developments International 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Medical Developments International (ASX:MVP) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Medical Developments International 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Medical Developments International's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Medical Developments International (ASX:MVP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medical Developments International Ltd (ASX:MVP) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Caribbean Drive, Scoresby, VIC, AUS, 3179

Website

https://www.medicaldev.com

Medical Developments International Ltd is a specialized healthcare company. It manufactures and distributes the pharmaceutical drug and medical and veterinary equipment. The company provides a range of products in the areas of pain management, asthma, and resuscitation, plus veterinary equipment. It is organized into three business units: Pharmaceuticals, Medical Devices, and Veterinary products. Majority of its revenue comes from Pharmaceuticals Unit which engages in the sale of Penthrox within Australia, New Zealand, Europe the UK and some sales in Canada, the Middle East, Asia and South Africa.

Medical Developments International (ASX:MVP) Headlines

No Headlines